272 results about "Lectin" patented technology

Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).

The invention discloses a normal-temperature bacteria liquid enteric-coated targeted colonization microcapsule and a preparation method thereof. The invention belongs to the technical field of biological medicine. The structure of the room-temperature bacterial liquid protection microcapsule is as follows: an inner layer is an activity maintaining layer and mainly consists of a sodium alginate-calcium chloride polyelectrolyte compound (the thickness is 50-100 microns); the middle layer is a pH response release layer and is mainly composed of hydroxypropyl methyl cellulose phthalate (HPMCP, dissolved at pH of 6.8 or above) and nano calcium carbonate particles (the particle size is 50nm, and the proportion is 10% w / w); the outer layer is a mucous membrane adhesion layer, and the main components of the mucous membrane adhesion layer comprise fucose modified chitosan (Fuc-CS, targeted colonic mucous membrane lectin protein) and carbomer 940 (pH sensitive adhesion polymer); the method is a microcapsule capable of preserving the bacterial liquid at normal temperature and accurately targeting colon release and adhesion colonization and a process thereof, the problem of flora activity loss caused by a freeze-drying process can be solved, in addition, the process does not need freeze-drying equipment, and the production cost is reduced.

The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.

The present invention relates to the process to prepare recombinant lectin having amino acid sequence of SEQ ID NO:1, wherein the process comprises fed-batch fermentation of a clone in a host cell at specific feeding rate with carbon to Nitrogen ratio of 3:1 to 6:1. The invention also relates to the process of purification of recombinant lectin having amino acid sequence of SEQ ID NO: 1.

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.

The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 2.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The application belongs to the technical field of biology and specifically relates to a method for analyzing glycans on single extracellular vesicles in a fluid sample. The method uses magnetic nanoparticles to capture and manipulate EVs, based on the specific affinity of lectins for specific glycan structures, uses polydisperse microdroplets to separate the captured EVs, realizes local signal amplification in the droplets through enzymatic reaction, adopts fluorescence microscopy to collect images of the droplets, and thus realizes identification and analysis of the glycan components on single EVs. The preparation process of the microdroplets formed by the oscillating emulsification method of the application makes the entire detection process more simple and fast, does not require any microfluidic chip and special device, and can be completed in a centrifugal tube, and all the microdroplets are generated in parallel and quickly, and the amount of microdroplets can be flexibly expanded. Moreover, compared with the traditional ELISA, the method has high sensitivity, low detection limit and small sample consumption.

Composition and methods for preventing or reducing inflammation resulting from nanoparticle administration to a subject are provided. In one embodiment a method of delivering an agent to a target organ of a subject, comprises administering to the subject a galectin inhibitor and a nanoparticle comprising the agent, wherein inflammation resulting from administration of the nanoparticle is reduced or prevented.

In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) and requires supplemental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.

The present invention relates to a double-stranded siRNA analogue for inhibiting expression of mannan-binding lectin-related serine protease 2 (MASP2), and a preparation method and use thereof, the double-stranded siRNA analogue can inhibit expression of MASP2, and is used for preventing and / or treating MASP2-related diseases and symptoms, such as MASP2-related diseases and disorders. The diseases and symptoms comprise IgA nephropathy, membranous nephropathy, lupus nephritis, thrombotic microangiopathy, systemic lupus erythematosus and the like.

The application of the primer for detecting the anti-disease gene of the Eriocheir sinensis in identifying the disease resistance of the parent of the Eriocheir sinensis comprises the following steps: (1) respectively extracting RNA (Ribonucleic Acid) of the Eriocheir sinensis, and carrying out reverse transcription to obtain cDNA (Complementary Deoxyribonucleic Acid) of the Eriocheir sinensis; (2) designing a primer combination according to the sequence of the lysozyme gene of the eriocheir sinensis and the sequence of the C-type lectin 4 gene, performing PCR amplification on the cDNA sample of the eriocheir sinensis by utilizing the primer combination to obtain a target fragment, and detecting and confirming that the target fragment is amplified by utilizing agarose gel electrophoresis; (3) obtaining a cDNA sequence by a first-generation sequencing means, carrying out sequence comparison, identifying SNP sites in gene coding regions of the lysozyme gene and the C-type lectin 4 gene, and analyzing the two genes and a combination thereof; and comparing the differences of the disease resistance of the genotypes, and screening to obtain the genotype with the strongest disease resistance and the combined marker primer thereof.

The present disclosure relates to methods of treating T-cell large granular lymphocytic leukemia (T-LGLL) with antibodies, or antigen-binding fragments thereof, that specifically bind to killer cell lectin-like receptor G1 (KLRG1), and methods for maintaining remission of T-cell large granular lymphocytic leukemia in a patient.

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

Certain aspects of the present disclosure relate to industrial scale production and recovery of lectin proteins. Certain aspects relate to recombinant gram-positive bacterial cells that produce heterologous lectin proteins. Certain other aspects relate to compositions and methods for recovering and / or purifying one or more lectins and lectin formulations with improved purity thereof.

The disclosure provides a chimeric antigen receptor (CAR) polypeptide having an antigen binding domain comprising an extracellular lectin which specifically binds to glycoproteins expressed on the surface of target cells. Also provided herein are engineered lymphocytes expressing the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods of treating cancer.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The invention discloses a saccharomyces cerevisiae genetically engineered bacterium for efficiently synthesizing mogroside V based on multi-compartment multi-metabolic pathways and a construction method of the saccharomyces cerevisiae genetically engineered bacterium. The preparation method comprises the following steps: anchoring an MVA pathway and a squalene synthesis pathway on the surface of a peroxisome membrane, and enabling mogrol synthetase and epoxy squalene cyclization enzyme ERG1 to form a linear polywheat complex through polypeptide interaction; then, through overexpression of MVA pathway key enzyme and introduction of an isopentenol utilization pathway, supply of precursor isopentenyl pyrophosphate and dimethyl allyl pyrophosphate in cytoplasm is increased, and squalene epoxidase ERG1 and mogrol synthetase are anchored in transmembrane ABC efflux protein PDR11 through polypeptide interaction; then anchoring the mogrol synthetase in the lipid droplet subcells; finally, the glucosyltransferase is displayed on the surface of the yeast cell wall through an alpha-lectin system, so that extracellular mogrol is converted into MG-V. The engineering bacterium improves the yield of mogroside V synthesized from the beginning in microorganisms, and has great industrial application value.

The present invention relates to the field of biopharmaceutical technology, and specifically discloses a nasal-to-brain targeted central nervous system nano-drug delivery system, its preparation method and application. The nasal-to-brain targeted central nervous system nano-drug delivery system includes a biotherapeutic drug and a lectin-conjugated liposome nanoparticle wrapped on the surface of the biotherapeutic drug; the biotherapeutic drug is a biomacromolecule encoded by mRNA; the lectin is AAL, and the raw materials of the liposome nanoparticle include SM102, DSPC, cholesterol, DMG-pSar25 and DSPE-PEG-MAL. By conjugating AAL with LNP of specific components, the present invention specifically recognizes and binds to the receptor fucose of target cells, which helps the nanomaterials to be endocytosed through the olfactory mucosa and delivered to the brain through the nose-brain pathway, targeting the delivery of biotherapeutic drugs, breaking through the blood-brain barrier, and significantly improving the targeting efficiency and nasal delivery efficiency.

The invention belongs to the field of analysis and testing, and particularly relates to WGA-ConA double lectin modified magnetic nanoparticles for broad-spectrum separation of pathogenic bacteria as well as a preparation method and application of the WGA-ConA double lectin modified magnetic nanoparticles. The invention provides a WGA-ConA double lectin modified magnetic nanoparticle for broad-spectrum separation of pathogenic bacteria. The capture efficiency of the WGA-ConA double lectin modified magnetic nanoparticle on staphylococcus aureus, listeria monocytogenes, escherichia coli, pseudomonas aeruginosa and the like is greater than or equal to 85% under the condition that the pH is 6.5-7.5.

The invention relates to a ligand targeting neutrophil and neurons as well as a preparation method and application of the ligand. The ligand for targeting the neutrophil and the neuron is prepared from the following raw materials in parts by weight: 30 to 50 parts of DSPE-PEG-Tet1, 2 to 3 parts of ketal thiol with carboxyl groups at two ends and 30 to 50 parts of a neutrophil targeting ligand, the neutrophil targeting ligand is one or more of sialic acid, an anti-CD66b antibody, an anti-CD177 antibody, an anti-CD16b antibody, N-formylmethionine peptide (fMLF) and an analogue thereof, a CXCR1 / CXCR2 binding peptide, an integrin binding peptide, a selectin ligand and lectin. According to the invention, sequential targeting of neutrophile granulocytes-neurons can be realized, target cells of ischemic lesions can be accurately protected, and the improvement effect on the cerebral infarction area of MCAO rats can be obviously enhanced.

The invention relates to the technical field of aquatic animal immune regulation and control, in particular to rHoLL-like stepped lectin-like recombinant protein as well as a preparation method and application thereof. The recombinant protein has pathogen-related molecular pattern recognition and combination capabilities, can promote aggregation of pathogens in a body fluid environment, and activates an aquatic animal complement system, so that the non-specific immune defense capability is enhanced. The preparation method comprises the following steps: amplifying a HoLL-like mature peptide coding sequence, constructing a recombinant expression vector, and converting the recombinant expression vector into an escherichia coli expression host for induced expression to obtain rHoLL-like lectin-like recombinant protein existing in an inclusion body form; and carrying out affinity chromatography purification on the inclusion body protein, and carrying out renaturation treatment in a manner of gradient reduction of denaturant concentration to obtain the rHoLL-like stepped lectin-like recombinant protein. The rHoLL-like stepped lectin-like recombinant protein has good biological safety, and can be applied to aquaculture as an aquatic animal immunopotentiator or a related biological product.

The invention relates to a chemoenzymatic synthesis method of a high-glucose-type homogeneity mucoprotein core structural domain. The method comprises the following steps: firstly, catalytically synthesizing a key alpha-linked glycosylated amino acid block Fmoc-GalNacalpha-Ser / Thr-OH at a low temperature (-20 DEG C to 0 DEG C); then assembling the building blocks on a repeated polypeptide skeleton rich in proline, serine and threonine at accurate intervals (3-5 amino acid residues) through a solid-phase peptide synthesis technology to form a'sugar chain growth scaffold '; then, a series of high-specificity glycosyl transferases are used for carrying out sequential and directional sugar chain enzymatic extension on the scaffold, and a uniform core structure (such as a core type 3) is constructed; and finally, performing high-efficiency purification by a three-step series method of size exclusion chromatography, ion exchange chromatography and lectin affinity chromatography. The technical bottleneck of inhomogeneity (lt, 70%) of glycoforms in a traditional method is overcome, the mucoprotein core fragment with glycoform homogeneity larger than or equal to 95% and bioactivity highly similar to that of natural mucoprotein can be prepared on a large scale, and the method has wide application prospects in the biomedical fields of mucous membrane protective agents, drug delivery carriers and the like.

The present invention relates to a composition for preventing or treating lupus or glomerulonephritis comprising a recombinant stabilized Galectin-9 protein. Specifically, the recombinant stabilized Galectin-9 protein of the present invention has been confirmed to exhibit safety in a systemic lupus erythematosus (SLE) animal model, reduce skin lesions, lymphadenopathy, and proteinuria caused by lupus, ameliorate lupus nephritis and glomerulonephritis, and decrease the concentration of anti-dsDNA antibodies in plasma. Accordingly, the recombinant stabilized Galectin-9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.

The invention discloses a galectin MsGal-3 and an application of the galectin MsGal-3 in resisting MSRV infection in micropterus salmoides. Galectin MsGal-3 (the accession number is PV454561) is obtained through screening and identification from a liver transcriptome of micropterus salmoides, a target gene is synthesized, plasmids are constructed, then an escherichia coli E.coli expression strain BL21 is adopted for induced expression, and MsGal-3 protein is obtained through purification and can be used for preventing and treating micropterus salmoides rhabdovirus infection.

Compositions and methods of glycosylated virus-like particles (VLPs) displaying user-defined antigens and optionally encapsidating TLR ligands for targeting dendritic cell lectins have been developed. The VLPs employ ligands for a DC lectin e.g., DC-SIGN to activate dendritic cells (DC) and drive proliferation of antigen-specific CD8 and CD4-T cells specific for a user-defined antigen, such as a tumor antigens. In some forms, the compositions include aryl-mannose ligands to effectively generate DC-mediated TH-1 T cell responses to the user-defined antigen.

The application belongs to the technical field of molecular biology, and particularly relates to a long oyster C-type lectin CgCLec-TM2 functional domain CRD recombinant protein and application. The amino acid sequence of the long oyster C-type lectin CgCLec-TM2 functional domain CRD recombinant protein is shown as SEQ ID NO. 1. The rCRD obtained by the application has binding capacity to various pathogen-associated molecular patterns (PAMPs), can bind and agglutinate various microorganisms, has a growth inhibiting effect on gram-negative bacteria Vibrio splendidus and Escherichia coli, and can be used for the development of bacteriostatic feed additives and new-type immune enhancers.

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

The invention relates to the technical field of molecular biology and immunity, in particular to urechis unicinctus C-type lectin and a preparation method and application thereof. The amino acid sequence of the urechis unicinctus C-type lectin is as shown in SEQ ID No. 1. The C-type lectin is a recombinant protein obtained by expression in escherichia coli. The recombinant protein can be widely combined and agglutinated with various gram-positive bacteria and gram-negative bacteria, and can promote the removal of pathogenic bacteria in urechis unicinctus. The recombinant C-type lectin can be used for preparing a bacterial agglutination preparation, an anti-bacterial infection preparation and the like, and is especially suitable for prevention and control of aquaculture pathogenic bacteria.